scholarly journals Nocturnal activation of melatonin receptor type 1 signaling modulates diurnal insulin sensitivity via regulation of PI3K activity

2018 ◽  
Vol 64 (3) ◽  
pp. e12462 ◽  
Author(s):  
Sharon Owino ◽  
Aida Sánchez-Bretaño ◽  
Cynthia Tchio ◽  
Erika Cecon ◽  
Angeliki Karamitri ◽  
...  
Keyword(s):  
Insulin Sensitivity ◽  
Receptor Type ◽  
Melatonin Receptor ◽  
Pi3k Activity

scholarly journals Orexin receptors 1 and 2 in serotonergic neurons differentially regulate peripheral glucose metabolism in obesity

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Xing Xiao ◽  
Gagik Yeghiazaryan ◽  
Simon Hess ◽  
Paul Klemm ◽  
Anna Sieben ◽  
...  
Keyword(s):  
Insulin Sensitivity ◽  
Glucose Tolerance ◽  
Glucose Homeostasis ◽  
Raphe Nucleus ◽  
Receptor Type ◽  
Serotonergic Neurons ◽  
Dynamic Regulation ◽  
Brown Adipose ◽  
Raphe Pallidus

AbstractThe wake-active orexin system plays a central role in the dynamic regulation of glucose homeostasis. Here we show orexin receptor type 1 and 2 are predominantly expressed in dorsal raphe nucleus-dorsal and -ventral, respectively. Serotonergic neurons in ventral median raphe nucleus and raphe pallidus selectively express orexin receptor type 1. Inactivation of orexin receptor type 1 in serotonin transporter-expressing cells of mice reduced insulin sensitivity in diet-induced obesity, mainly by decreasing glucose utilization in brown adipose tissue and skeletal muscle. Selective inactivation of orexin receptor type 2 improved glucose tolerance and insulin sensitivity in obese mice, mainly through a decrease in hepatic gluconeogenesis. Optogenetic activation of orexin neurons in lateral hypothalamus or orexinergic fibers innervating raphe pallidus impaired or improved glucose tolerance, respectively. Collectively, the present study assigns orexin signaling in serotonergic neurons critical, yet differential orexin receptor type 1- and 2-dependent functions in the regulation of systemic glucose homeostasis.

Melatonin Receptor Type 1 Signals to Extracellular Signal-Regulated Kinase 1 and 2 via Giand GsDually Coupled Pathways in HEK-293 Cells

Biochemistry ◽  
2014 ◽  
Vol 53 (17) ◽  
pp. 2827-2839 ◽  
Author(s):  
Linjie Chen ◽  
Xiaobai He ◽  
Yaping Zhang ◽  
Xiaopan Chen ◽  
Xiangru Lai ◽  
...  
Keyword(s):  
Receptor Type ◽  
Melatonin Receptor ◽  
Hek 293 ◽  
Extracellular Signal Regulated Kinase ◽  
Hek 293 Cells ◽  
293 Cells ◽  
Extracellular Signal

scholarly journals Removing melatonin receptor type 1 signaling leads to selective leptin resistance in the arcuate nucleus

2019 ◽  
Vol 67 (2) ◽  
Author(s):  
Daniella Buonfiglio ◽  
Cynthia Tchio ◽  
Isadora Furigo ◽  
José Donato ◽  
Kenkichi Baba ◽  
...  
Keyword(s):  
Arcuate Nucleus ◽  
Receptor Type ◽  
Leptin Resistance ◽  
Melatonin Receptor

scholarly journals Removal of Melatonin Receptor Type 1 Induces Insulin Resistance in the Mouse

Obesity ◽  
2010 ◽  
Vol 18 (9) ◽  
pp. 1861-1863 ◽  
Author(s):  
Susana Contreras-Alcantara ◽  
Kenkichi Baba ◽  
Gianluca Tosini
Keyword(s):  
Insulin Resistance ◽  
Receptor Type ◽  
Melatonin Receptor

Melatonin Receptor as a Drug Target for Neuroprotection

2020 ◽  
Vol 14 (2) ◽  
pp. 150-164 ◽  
Author(s):  
Pawaris Wongprayoon ◽  
Piyarat Govitrapong
Keyword(s):  
The Body ◽  
Melatonin Receptors ◽  
Receptor Type ◽  
Substantia Nigra Pars Compacta ◽  
Melatonin Receptor ◽  
Amyloid Aβ ◽  
Disease Modifying Agents ◽  
Cerebral Ischemic ◽  
Cerebral Ischemic Reperfusion

Background:: Melatonin, a neurohormone secreted from the pineal gland, circulates throughout the body and then mediates several physiological functions. The pharmacological effects of melatonin can be mediated through its direct antioxidant activity and receptor-dependent signaling. Objective: This article will mainly review receptor-dependent signaling. Human melatonin receptors include melatonin receptor type 1 (MT1) and melatonin receptor type 2 (MT2), which are widely distributed throughout the brain. Result: Several lines of evidence have revealed the involvement of the melatonergic system in different neurodegenerative diseases. Alzheimer’s disease pathology negatively affects the melatonergic system. Melatonin effectively inhibits β-amyloid (Aβ) synthesis and fibril formation. These effects are reversed by pharmacological melatonin receptor blockade. Reductions in MT1 and MT2 expression in the amygdala and substantia nigra pars compacta have been reported in Parkinson’s disease patients. The protective roles of melatonin against ischemic insults via its receptors have also been demonstrated. Melatonin has been reported to enhance neurogenesis through MT2 activation in cerebral ischemic/reperfusion mice. The neurogenic effects of melatonin on mesenchymal stem cells are particularly mediated through MT2. Conclusion: Understanding the roles of melatonin receptors in neuroprotection against diseases may lead to the development of specific analogs with specificity and potency greater than those of the original compound. These successfully developed compounds may serve as candidate preventive and disease-modifying agents in the future.

Sign in / Sign up

Export Citation Format

Share Document